Serving the Lesbian, Gay, Bisexual and Transgender community since 1994

The second-oldest LGBT organisation in South Africa, OUT provides stigma-free HIV, sexual health and other services to gay, bisexual and MSM communities. We also work to eradicate LGBT+ hate crimes and discrimination while assisting and supporting victims.

FDA approves first monthly injectable HIV treatment

In a major development in the treatment of HIV, a once-a-month injection to replace the current daily pill regime has been approved by the US Food and Drug Administration (FDA).

The agency approved Cabenuva (an injectable combination of the drugs cabotegravir and rilpivirin) as a complete treatment of HIV type 1 (the most common type of HIV) infection in adults.

The approval applies to HIV positive individuals who are virologically suppressed on a stable antiretroviral (ARV) regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.

This is the first FDA-approved injectable, complete regimen for HIV-infected adults that is administered once a month.

“Currently, the standard of care for patients with HIV includes patients taking daily pills to adequately manage their condition. This approval will allow some patients the option of receiving once-monthly injections in lieu of a daily oral treatment regimen,” said John Farley, director of the Office of Infectious Diseases in the FDA’s Center for Drug Evaluation and Research. “Having this treatment available for some patients provides an alternative for managing this chronic condition.”

Those who are eligible to convert to the once-a-month injection must first take cabotegravir and rilpivirine for one month prior to starting treatment with Cabenuva to ensure that the medications are well-tolerated.

“Today’s FDA approval of Cabenuva represents a shift in the way HIV is treated, offering people living with HIV a completely new approach to care. Cabenuva reduces the treatment dosing days from 365 days to 12 days per year,” said Lynn Baxter, Head of North America, ViiV Healthcare, which developed the new treatment.

The safety and efficacy of Cabenuva were established through two clinical trials in 1,182 HIV-infected adults.

It is not yet known if and when the injectable treatment will be approved for use in South Africa.

Have you been threatened, hit, raped or had your property damaged or stolen because you are gay, lesbian, bisexual, transgender or intersex (LGBTI)? Then you have been a victim of a hate crime.
OUT offers exciting training to mainstream service providers and other interested parties. The training assists individuals to understand themselves as sexual beings.
Currently OUT distributes safer sex packs to a range of venues in Tshwane that are utilised by gay men and lesbian women. These packs also include responsible sex messaging, appropriate barrier methods and lube.
OUT's Engage Men’s Health project offers free and confidential sexual health services to gay, bisexual and other men who have sex with men (MSM).